FDA acts to remove unproven, potentially harmful treatment used in ‘stem cell’ centers targeting vulnerable patients – PR Newswire (press release)
|
FDA acts to remove unproven, potentially harmful treatment used in ‘stem cell‘ centers targeting vulnerable patients
PR Newswire (press release) The seizure comes after recent FDA inspections at StemImmune Inc. and the California Stem Cell Treatment Centers confirmed that the vaccine was used to create an unapproved stem cell product (a combination of excess amounts of vaccine and stromal … |
EurekAlert (press release) |
Gene therapy using ‘junk DNA’ could lower risk for heart disease
EurekAlert (press release) Although previous research has shown that lncRNAs can be important, this is the first study to show that they could potentially be used to treat a human disease using gene therapy. Junk genes could one day offer a framework for treating people with … |
|
US FDA to remove unproven, potentially harmful treatment used in ‘stem cell‘ centers
Times of India Fda-Seizure comes after fda inspections at stemimmune, california stem cell treatment centers confirmed vaccine used to create an unapproved stem cell product. * Fda says u.s. Department of justice filed seizure complaint, on behalf of fda, in u.s … |
|
Statement from FDA Commissioner Scott Gottlieb, MD on the FDA’s new policy steps and enforcement efforts to ensure …
FDA.gov Recent advances in our basic knowledge of the pathways involved in tissue damage and regeneration have combined with remarkable progress in adult stem cell biology to put us at a genuine inflection point in the history of medicine. The prospect of … |
|
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
PR Newswire (press release) The acquisition will provide CSL Behring with Calimmune’s pre-clinical asset, CAL-H, an HSC gene therapy for the treatment of sickle cell disease and β-thalassemia, which complements CSL Behring’s current product portfolio and deep expertise in … |
|
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
Benzinga VBI-1901 is a novel immunotherapy developed using VBI’s eVLP technology to target CMV-positive (CMV+) tumors, including glioblastoma multiforme (GBM), the company’s lead immuno-oncology program. Dr. Anderson will present data in animal models … |